Abstract
Techniques for modulating immune cells for cancer therapy have been widely studied. One key approach that is being clinically tested is developing tumor-destructive cell-mediated immune responses by regulating co-stimulatory molecules. 4-1BB (CD137), a member of the TNF receptor family, is expressed following activation of T and NK cells. Recently, it has been reported that DCs also express 4-1BB. Cross-linking of 4-1BB provides a potent co-stimulatory signal for lymphocytes via signal transduction pathways that modulate a number of cellular responses. One remarkable response is stimulation of anti-tumor activity in vivo and in vitro. We here review the potential role of 4-1BB in cancer immunotherapy focusing on the cellular and molecular mechanisms involved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD / drug effects
-
Antigens, CD / immunology
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
CD8-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / metabolism
-
Humans
-
Immunotherapy
-
Lymphocyte Activation
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Receptors, Nerve Growth Factor / antagonists & inhibitors*
-
Receptors, Nerve Growth Factor / drug effects
-
Receptors, Nerve Growth Factor / immunology
-
Receptors, Tumor Necrosis Factor / antagonists & inhibitors*
-
Receptors, Tumor Necrosis Factor / drug effects
-
Receptors, Tumor Necrosis Factor / immunology
-
Signal Transduction / immunology
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocyte Subsets / metabolism
-
Tumor Necrosis Factor Receptor Superfamily, Member 9
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antineoplastic Agents
-
Receptors, Nerve Growth Factor
-
Receptors, Tumor Necrosis Factor
-
TNFRSF9 protein, human
-
Tumor Necrosis Factor Receptor Superfamily, Member 9